Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by A. De Stefano.
Annals of Oncology | 2009
Chiara Carlomagno; A. Farella; L. Bucci; Francesco Paolo D'Armiento; G. Pesce; Stefano Pepe; L. Cannella; Roberto Pacelli; A. De Stefano; R. Solla; Massimo D'Armiento; S. De Placido
BACKGROUNDnPreoperative chemoradiation is now standard treatment for stages II-III rectal cancer. Capecitabine (CAP) and oxaliplatin (OX) are synergistic with radiotherapy (RT) and active in colorectal neoplasms.nnnPATIENTS AND METHODSnTwo cycles of CAP 825 mg/m(2) b.i.d. (days 1-14) and OX 50 mg/m(2) (days 1 and 8) every 3 weeks were given concomitantly with pelvic conformal RT (45 Gy). Patients with a > or =T3 and/or node-positive rectal tumour were eligible. The pathologic tumour response was defined according to the tumour regression grade (TRG) scale.nnnRESULTSnForty-six patients were enrolled. Gastrointestinal adverse events were mostly G1-G2; only two patients experienced G3 vomiting and diarrhoea and six patients had G1 peripheral neuropathy. Haematological toxicity was rare. G2 proctitis and anal pain occurred in two patients. Pathological complete response (TRG1) was observed in nine patients (20.9%; 95% CI 8.7%-33.1%); TRG2 in 19 patients (44.2%); TRG3 in 12 patients (27.9%); and TRG4 in three patients (7%). Overall, nine patients recurred: five with distant metastases, one with local recurrence, and three with both local recurrence and distant metastases.nnnCONCLUSIONSnCAP-OX-RT as preoperative treatment for rectal cancer induces a remarkable rate of complete or near-complete pathologically documented response and is well tolerated.
British Journal of Cancer | 2012
Umberto Malapelle; Chiara Carlomagno; Maria Salatiello; A. De Stefano; C. De Luca; Roberto Bianco; Roberta Marciano; Carolina Cimminiello; Claudio Bellevicine; S. De Placido; Giancarlo Troncone
Background:Anti-epidermal growth factor receptor (EGFR) monoclonal antibodies are restricted to KRAS wild-type (WT) metastatic colorectal cancers (mCRCs), usually identified by direct sequencing, that may yield false negative results because of genetic heterogeneity within the tumour. We evaluated the efficiency of high-resolution melting analysis (HRMA) in identifying KRAS-mutant (MUT) tumours.Methods:We considered 50 mCRC patients scored as KRAS-WT by direct sequencing and treated with cetuximab-containing chemotherapy, and tested the correlations between HRMA findings and response rate (RR), progression-free (PFS) and overall survival (OS).Results:Aberrant melting curves were detected in four (8%) cases; gene cloning confirmed these mutations. Response rate (RR) of HRMA KRAS-WT patients was 28.3%. There was no response in HRMA KRAS-MUT patients. Disease control rate (responsive plus stable disease) was 58.7% in HRMA KRAS-WT patients and 25% in HRMA KRAS-MUT patients. There was no correlation between HRMA KRAS status and RR (P=0.287) or disease control (P=0.219). Median PFS (4.8 vs 2.3 months; hazard ratio (HR)=0.29, P=0.02) and OS (11.0 vs 2.7 months; HR=0.11, P=0.03) were significantly longer for the HRMA KRAS-WT than for HRMA KRAS-MUT patients.Conclusions:High-resolution melting analysis identified 8% more KRAS-MUT patients not responding to cetuximab-containing regimens, suggesting that HRMA may be more effective than direct sequencing in selecting patients for anti-EGFR antibodies.
Journal of Clinical Oncology | 2010
A. De Stefano; L. Cannella; Chiara Carlomagno; Anna Crispo; R. Bianco; Roberta Marciano; Stefano Pepe; S. De Placido
Annals of Oncology | 2008
Chiara Carlomagno; Francesco Paolo D'Armiento; Anna Crispo; G. Della Vittoria Scarpati; Massimo D'Armiento; Monica Marra; L. Cannella; A. De Stefano; M. Colantuoni; S. Alfieri; S. De Placido; Stefano Pepe
Annals of Oncology | 2018
Antonio Avallone; Guglielmo Nasti; Gerardo Rosati; Chiara Carlomagno; Carmela Romano; Domenico Bilancia; A. De Stefano; Lucrezia Silvestro; Alessandro Ottaiano; Antonino Cassata; Franco Bianco; Francesco Izzo; Paolo Delrio; E De Gennaro; Rossana Casaretti; Salvatore Tafuto; V Albino; U Pace; Secondo Lastoria; Ciro Gallo; Alfredo Budillon; Maria Carmela Piccirillo
Annals of Oncology | 2018
A. De Stefano; Guglielmo Nasti; A Febbraro; Gerardo Rosati; F Giuliani; D Santini; G Aprile; Mario Scartozzi; Franco Silvestris; G Luppi; I Lolli; C Mastroianni; S Leo; Vincenzo Montesarchio; C Gridelli; Carmelo Pozzo; E Sperti; D Giannarelli; Alfredo Budillon; Antonio Avallone
Annals of Oncology | 2018
Antonio Avallone; Paolo Delrio; Gugliemo Nasti; Antonino Cassata; Lucrezia Silvestro; A. De Stefano; Secondo Lastoria; Rossana Casaretti; Carmela Romano; Alessandro Ottaiano; E. Di Gennaro; Anna Nappi; Piera Maiolino; Ernesta Cavalcanti; Antonella Petrillo; Fabiana Tatangelo; D Giannarelli; J Galon; P A Ascierto; Alfredo Budillon
Annals of Oncology | 2018
Alfredo Budillon; Paolo Delrio; Biagio Pecori; Fabiana Tatangelo; E. Di Gennaro; Carmela Romano; V D'Angelo; Pietro Marone; C Granata; E Cavalacanti; A. De Stefano; U Pace; Franco Bianco; Antonella Petrillo; Secondo Lastoria; Gerardo Botti; Paolo Muto; Francesco Perrone; Maria Carmela Piccirillo; Antonio Avallone
Annals of Oncology | 2018
Alessandro Ottaiano; Monica Capozzi; C De Divitiis; Antonino Cassata; A. De Stefano; Salvatore Tafuto; Antonio Avallone; Gugliemo Nasti
Annals of Oncology | 2017
Antonio Avallone; Guglielmo Nasti; Gerardo Rosati; Chiara Carlomagno; Carmela Romano; Domenico Bilancia; A. De Stefano; Alessandro Ottaiano; Antonino Cassata; Lucrezia Silvestro; Salvatore Tafuto; Franco Bianco; Paolo Delrio; Francesco Izzo; E. Di Gennaro; Secondo Lastoria; Ciro Gallo; Francesco Perrone; Alfredo Budillon; Maria Carmela Piccirillo